


# A Phase 3 Study to Evaluate Eptinezumab for the Preventive Treatment of Chronic Migraine: Results of the PROMISE-2 (PREvention Of Migraine via Intravenous eptinezumab Safety and Efficacy–2) Trial

Richard B. Lipton,<sup>1</sup> Peter J. Goadsby,<sup>2</sup> Julia Azimova,<sup>3</sup> Messoud Ashina,<sup>4</sup> Egilius L.H. Spierings,<sup>5</sup> Paul Winner,<sup>6</sup> Barbara Schaeffler,<sup>7</sup> David Biondi,<sup>7</sup> Suman Bhattacharya,<sup>7</sup> Jeff Smith,<sup>8</sup> Roger Cady<sup>7</sup>

Poster # PFO2


Eptinezumab (ALD403) is an IgG1 anti-CGRP monoclonal antibody administered quarterly by iv infusion, allowing for 100% bioavailability



## PROMISE 2: Eptinezumab Phase 3 Chronic Migraine Study Design

N=1072

Men and women aged 18–65 years with  $\geq 15$  to  $\leq 26$  headache days, of which  $\geq 8$  assessed as migraine days during 28-day screening period




<sup>1</sup>Montefiore Headache Center, Albert Einstein College of Medicine, Bronx, NY; <sup>2</sup>NIHR and Wellcome Trust King's Clinical Research Facility, King's College London, UK; <sup>3</sup>University Headache Clinic, Moscow, Russia; <sup>4</sup>Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; <sup>5</sup>MedVadis Research, Watertown, MA; <sup>6</sup>Premiere Research Institute, Palm Beach Headache Center, West Palm Beach, FL; <sup>7</sup>Alder BioPharmaceuticals, Inc., Bothell, WA; <sup>8</sup>Alder BioPharmaceuticals Ltd, Dublin, Republic of Ireland 1

# Eptinezumab Significantly Reduced Mean MMD Weeks 1–12: Primary Endpoint

Poster # PFO2

■ Placebo (n=366) ■ Eptinezumab 100 mg (n=356) ■ Eptinezumab 300 mg (n=350)



- Eptinezumab 100 and 300 mg significantly decreased mean MMD from baseline vs placebo over Weeks 1–12 after the first infusion


# Eptinezumab Subjects Achieved High Rates of $\geq 50\%$ and $\geq 75\%$ Migraine Response: Key Secondary Endpoints

Poster # PFO2


## Migraine Responder Rates With Eptinezumab

■ Placebo (n=366) ■ Eptinezumab 100 mg (n=356) ■ Eptinezumab 300 mg (n=350)

### Weeks 1–12




### Weeks 1–4



\*p < 0.0001 vs placebo; Migraine responder rates, % of subjects with prespecified reduction from baseline in MMD.

# Day 1 Reduction From Baseline in Percentages of Subjects With a Migraine Maintained, on Average, Through 28 Days\*

Poster # PFO2



\*Day 1 % of subjects with a migraine in eptinezumab vs placebo groups ( $p < 0.0001$  for both doses) and daily % of subjects with a migraine averaged weekly for Days 1–28 in eptinezumab vs placebo groups ( $p < 0.0001$  for both doses)

## Conclusions

- Eptinezumab subjects showed significant reductions in monthly migraine activity across primary and all key secondary endpoints
- Subjects treated with eptinezumab 300 mg experienced significantly fewer days with migraine
  - >33% of subjects achieved a  $\geq 75\%$  reduction in MMD
  - >61% of subjects achieved a  $\geq 50\%$  reduction in MMD
- The percentage of subjects with a migraine on Day 1 postinfusion dropped by  $\geq 50\%$  compared with baseline and reductions were sustained, on average, through Day 28
- For initial presentation of the data for 2 quarterly infusions of eptinezumab, please stop by Poster PF110LB